Gilead Sciences HIV Prevention Treatment Shows 100% Effectiveness in Phase 3 Trial
By Dean Seal
Gilead Sciences said an interim analysis of its lenacapavir study showed 100% efficacy in HIV prevention in cisgender women, resulting in a recommendation that the treatment be opened to all trial participants.
The biopharmaceutical company said the phase 3 trial of its twice-yearly injectable HIV-1 capsid inhibitor met key efficacy endpoints of showing superiority to once-daily oral Truvada and background HIV incidence.
The independent data monitoring committee has recommended that Gilead stop the blinded phase of the trial and offer open-label lenacapavir to all participants.
Gilead said this is the first phase 3 HIV prevention trial to show zero infections.
The company expects results from the lenacapavir program's other phase 3 trial in late 2024 or early 2025. That trial assesses the treatment for pre-exposure prophylaxis, or PrEP, in cisgender men who have sex with men, transgender men, transgender women and gender non-binary individuals who have sex with partners assigned male at birth.
Gilead said the regulatory filing for lenacapavir for PrEP will include the results of both Phase 3 trials.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
June 20, 2024 09:51 ET (13:51 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Obesity Drug Stocks: Why It Will Be ‘Exceptionally Difficult’ to Dethrone Eli Lilly and Novo Nordisk
-
What Does Chipotle’s Stock Split Mean for Investors?
-
5 Stocks to Buy Before the Fed Cuts Interest Rates in 2024
-
Markets Brief: Inflation Is Back In the Spotlight
-
What’s Happening In the Markets This Week
-
What a Strong Economy Now Means for the Rest of 2024
-
4 Wide-Moat Stocks to Buy for the Long Term While They’re Undervalued Today
-
Markets Brief: Four Stocks Made Up 80% of the Gains. Can It Last?
-
2 Top E-Commerce Stock Picks
-
Our Top Pick for Investing in US Renewable Energy
-
Micron Earnings: We Raise Our DRAM Forecast and Valuation Behind Stronger Pricing Assumptions
-
10 Undervalued Wide-Moat Stocks
-
What Is a Stock Split?
-
10 Best Value Stocks to Buy for the Long Term
-
A Wide-Moat Stock to Invest in That’s 35% Undervalued
-
Airbus: We Believe Investors May Be Overreacting to Lowered Guidance and Charge